Clinical Trials Logo

Clinical Trial Summary

Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction. Exploratory research objective: To explore the changes of endogenous substances in vivo before and after drug administration, to interpret the mechanism of drug action through metabolomics and systems biology methods, and to find potential clinical biomarkers for exploratory subgroup analysis of clinical trials.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Chronic Heart Failure With Preserved Ejection Fraction
  • Heart Failure

NCT number NCT04944706
Study type Interventional
Source Tasly Pharmaceutical Group Co., Ltd
Contact Rui Liu
Phone 022-86343626
Email liurui2@tasly.com
Status Recruiting
Phase Phase 2
Start date July 27, 2021
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT03547583 - Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF Phase 2